预约演示
更新于：2025-07-14
Lacidipine
拉西地平
更新于：2025-07-14
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 意大利 (1991-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C26H33NO6 |
InChIKeyGKQPCPXONLDCMU-CCEZHUSRSA-N |
CAS号103890-78-4 |
关联
54
项与 拉西地平 相关的临床试验CTR20250803
拉西地平片（4 mg）单次空腹状态下在健康受试者中的生物等效性试验
CTR20251608
拉西地平片在健康人群中的生物等效性试验
CTR20251609
拉西地平片在健康人群中的生物等效性试验
100 项与 拉西地平 相关的临床结果
登录后查看更多信息
100 项与 拉西地平 相关的转化医学
登录后查看更多信息
100 项与 拉西地平 相关的专利（医药）
登录后查看更多信息
8,379
项与 拉西地平 相关的文献（医药）2025-12-31BLOOD PRESSURE
Association between ACEI/ARB and short-term prognosis in dialysis patients with hypertension admitted to intensive care unit
Article
作者: Zheng, Jingang ; Li, Jiahui ; Duo, Xiaoyan ; Ye, Zixiang ; Che, Wuqiang ; Gao, Yanxiang ; An, Shuoyan ; Li, Xingliang
INTRODUCTION:
To investigate the association between angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) and short-term prognosis in dialysis patients with hypertension admitted to intensive care unit (ICU).
METHODS:
Patients with a diagnosis of hypertension and dialysis who received antihypertensive agents during hospitalisation were included. Based on whether treated with ACEI/ARB, patients were divided to ACEI/ARB group and non- ACEI/ARB group. In-hospital mortality and 30-day all-cause mortality were compared between the two groups in the overall participants and after propensity score matching.
RESULTS:
The study included 647 patients, among which 227 (34.70%) were treated with ACEI/ARB. Compared to the non-ACEI/ARB group, fewer patients in the ACEI/ARB group suffered from atrial fibrillation/flutter (17.2% vs 31.9%, p < 0.001). The overall hospital mortality rate was 5.1%, and 9.0% of patients died during the 30-day follow-up period. ACEI/ARB group were with better clinical outcomes during hospitalisation (2.2% vs 6.7%, p = 0.023) and after 30-day follow-up (5.3% vs 11.0%, p = 0.016). ACEI/ARB treatment was independently associated with lower risk of hospital mortality (OR 0.24, 96% CI: 0.051 - 0.82, p = 0.038) and 30-day mortality (HR 0.36, 95% CI:0.15-0.89, p = 0.029) after adjusting confounding factors. After propensity score matching (PSM, 112 pairs), the ACEI/ARB group showed higher in-hospital (99.1% vs 91.1%, p = 0.013) and 30-day (95.5% vs 88.4%, p = 0.048) survival rates compared to the control group. ACEI/ARB was identified as an independent protector for 30-day mortality in the matched cohort (HR 0.33, 95% CI: 0.11-0.95, p = 0.041).
CONCLUSION:
ACEI/ARB treatment showed a significant association with improved in-hospital and 30-day outcomes in dialysis patients with hypertension in the ICU.
2025-12-31RENAL FAILURE
Age, creatinine, and ejection fraction score is a risk factor for acute kidney injury after surgical aortic valve replacement
Article
作者: Tian, Xiaqiu ; Zhang, Ran ; Wu, Tingting ; Chen, Jing ; Li, Rui ; Hou, Xiaotong
BACKGROUND:
The incidence of acute kidney injury (AKI) increases after surgical aortic valve replacement (SAVR). This study aimed to characterize the risk factors of AKI after SAVR.
METHODS AND RESULTS:
We conducted a retrospective registry study based on data from 299 consecutive patients undergoing SAVR. At 48 h after SAVR, 41 patients developed AKI. There was a significantly higher prevalence of older age, higher body mass index (BMI), and diabetes mellitus in the AKI group. Previous use of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker (ACEI/ARB) and β-blocker, intake and output volumes within 24 h, mechanical ventilation time, length of intensive care unit and hospital stay, baseline creatinine, baseline, 24 h, and 48 h estimated glomerular filtration rate were strongly associated with the incidence of AKI. BMI >24, history of hypertension, use of ACEI/ARB and β-blocker, and mechanical ventilation time were associated with AKI. Univariate logistic regression indicated that overweight, hypertension, use of ACEI/ARB and β-blocker, and mechanical ventilation time were associated with AKI. Notably, the ACEF score was an independent predictor of AKI. The receiver operating characteristic curve was employed to assess the ACEF score for predicting AKI and the best cutoff was 1.1. After dividing ACEF into quartiles, each one-unit increment in ACEF led to a 2.27-fold risk in the incidence of AKI among patients.
CONCLUSIONS:
AKI is a generalizable phenomenon occurring frequently after SAVR. The ACEF score is an independent predictor of AKI among patients undergoing SAVR.
2025-08-01IJC Heart & Vasculature
Angiotensin-converting enzyme inhibitors for aortic stenosis: a drug-target Mendelian randomization study
Letter
作者: Woolf, Benjamin ; Gill, Dipender ; Bhindi, Ravinay ; Ciofani, Jonathan L ; Allahwala, Usaid K ; Han, Daniel
100 项与 拉西地平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 意大利 | 1991-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性高血压 | 临床3期 | - | 1995-06-01 | |
| 稳定型心绞痛 | 临床2期 | - | 1998-04-01 | |
| 溃疡性结肠炎 | 临床前 | 中国 | 2024-09-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 89 | TENS therapy at 10 Hz | 壓遞夢衊遞糧範觸糧製(鑰製襯鑰鑰壓壓廠製遞) = 艱網築衊簾鏇網簾窪鹽 構鏇願簾蓋範鏇鹹鬱夢 (獵醖鑰願廠鑰壓鏇憲製 ) | 积极 | 2024-05-01 | ||
N/A | 10 | 艱衊壓糧艱繭範窪顧遞(廠壓築憲網壓遞簾襯鏇) = Dyspnea and lower limb fatigue were similar in any of the 3 conditions 範壓淵獵廠艱窪衊膚壓 (顧範積憲齋鏇衊憲鏇遞 ) 更多 | - | 2019-09-28 | |||
N/A | - | TENS | 齋鏇遞遞壓鹽衊觸夢鹹(壓憲網繭構衊鏇廠選襯) = 鏇鹽糧簾襯淵構淵築襯 遞製襯構築鏇觸窪構觸 (糧選遞廠膚膚艱廠衊鏇 ) 更多 | 积极 | 2015-11-01 | ||
No TENS | 齋鏇遞遞壓鹽衊觸夢鹹(壓憲網繭構衊鏇廠選襯) = 醖構簾製夢鏇鬱齋願築 遞製襯構築鏇觸窪構觸 (糧選遞廠膚膚艱廠衊鏇 ) 更多 | ||||||
临床4期 | 315 | 鹽餘繭膚糧構蓋觸觸網(衊糧糧齋衊遞觸壓醖齋) = 廠鏇鬱獵艱顧窪鹽壓襯 齋廠窪糧鑰鹽構糧範網 (築蓋餘衊衊範鬱窪餘鬱 ) | - | 2013-06-01 | |||
Amlodipine besylate | 鹽餘繭膚糧構蓋觸觸網(衊糧糧齋衊遞觸壓醖齋) = 範願齋餘廠觸醖築網糧 齋廠窪糧鑰鹽構糧範網 (築蓋餘衊衊範鬱窪餘鬱 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用